ACTIVE INGREDIENT: Letrozole
STRENGTH & PACK SIZE & GMS CODES:
2.5 mg Film-Coated Tablets x 30 ~ 24525
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breastcancer.
Extended adjuvant treatment of hormone-dependent invasive breast cancer in postmenopausal women who have received prior standard adjuvant tamoxifen therapy for 5 years.
First-line treatment in postmenopausal women with hormone-dependent advanced breast cancer. Advanced breast cancer after relapse or disease progression, in women with natural or artificially induced postmenopausal
endocrine status, who have previously been treated with anti-oestrogens.
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive, HER-2 negative breast cancer where chemotherapy is not suitable and immediate surgery not indicated.
Efficacy has not been demonstrated in patients with hormone receptor negative breast cancer.
Download Letzo 2.5mg SPC and Patient Information Leaflet here